Xenon Pharmaceuticals Inc. XENE Cash Flow

Xenon pharmaceuticals inc. (XENE)
CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities:
Net loss
-37,738	-41,595	-38,777	-44,289	-42,083	-34,497	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-27,251	-22,997	-20,930	-17,043	-9,859	-15,752	-10,591	2,427	2,489	13,018	0	0	0
Items not involving cash:
Depreciation
454	429	424	463	515	586	592	617	634	649	668	667	747	864	982	1,077	1,113	1,038	959	880	770	738	0	0	0
Amortization of discount on term loan
537	525	516	375	337	284	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax expense
-114	-133	-84	-55	-35	-105	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
3,448	2,924	2,142	2,217	2,453	2,625	2,643	2,523	2,421	2,236	2,162	2,231	2,047	2,161	2,116	1,289	-898	3,729	3,454	3,833	5,793	760	0	0	0
Deferred tenant inducements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-63	-65	-65	-66	0	0	0
Unrealized foreign exchange (gain) loss
-243	302	-216	-15	-356	-646	-380	249	881	1,474	874	-389	-634	1,300	595	-2,041	-1,502	-6,902	-5,506	-2,417	-3,175	-72	0	0	0
Unrealized gain on marketable securities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on termination of collaboration agreement (note 13c)
-	-	-	-	-	4,398	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
1,497	653	123	59	-260	-280	-40	-87	203	232	-470	-459	-192	-121	318	471	-829	107	119	-167	789	-209	0	0	0
Prepaid expenses and other current assets
1,096	820	-519	213	104	928	869	170	226	-613	-178	-1,257	-893	-571	-807	1,531	1,352	1,214	1,931	370	382	573	0	0	0
Prepaid expenses, long term
-	-	-	-	-	-	-	-285	-269	-178	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
2,404	4,541	3,558	3,509	3,359	783	1,235	-667	-1,205	-3	-780	809	830	484	739	368	967	17	127	294	-327	518	0	0	0
Deferred revenue
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-9,003	-4,632	-31,609	-38,267	-35,201	-34,724	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investing activities:
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-157	-2,513	-5,635	-8,724	-11,622	-13,149	-14,221	-15,103	-14,410	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-21,083	-19,567	-20,144	-20,505	-17,500	-18,103	-15,807	-4,638	-4,439	266	0	0	0
Purchases of property, plant and equipment
1,552	1,240	815	789	661	507	400	395	359	315	280	312	333	279	394	566	550	551	1,184	1,222	1,133	1,529	0	0	0
Purchases of marketable securities
213,651	140,494	102,936	123,267	103,179	77,002	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	15,254	0	0	0
Proceeds from marketable securities
102,990	75,443	85,170	74,378	62,873	48,522	45,628	36,663	56,538	52,616	0	0	0	-	-	-	-	10,745	12,481	10,789	12,394	13,539	0	0	0
Net cash used in investing activities
-112,213	-66,291	-18,581	-49,678	-40,967	-28,987	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities:
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-38,512	-47,842	-15,759	-6,939	8,620	10,194	11,377	-2,741	-1,415	-3,244	0	0	0
Issuance of common shares, net of issuance costs (note 10a)
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42,853	42,766	42,644	0	0	0
Deferred financing fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,533	0	0	0
Issuance of common shares pursuant to exercise of stock options
78	122	113	175	227	288	262	182	122	177	225	227	262	132	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
129,930	27,518	121	77,532	111,530	111,591	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase (decrease) in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	24,094	23,964	23,954	147	195	278	42,659	42,063	41,644	41,124	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-86	486	753	621	34	-403	1,889	615	-1,839	-1,168	-5,744	-6,491	-5,425	-4,820	-4,070	0	0	0
Increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	24,345	-2,960	3,391	-39,447	-12,120	-35,904	-41,556	-11,334	-29,136	-9,853	-13,375	31,738	29,259	30,970	34,076	0	0	0
Supplemental disclosures:
Interest paid
893	917	925	865	720	561	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest received
2,679	2,216	2,487	2,047	1,635	1,067	714	572	826	740	624	594	284	341	370	595	650	659	0	0	0	-	-	-	-
Cash paid for operating lease
635	634	628	634	630	624	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest received
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Supplemental disclosures of non-cash transactions:
Fair value of stock options exercised on a cashless basis
0	-	0	0	0	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of preferred shares in exchange for common shares (note 11d)
-	-	-	-	-	21,825	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common shares on conversion of subscription rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124	0	0	0
Fair value of options exercised on a cashless basis
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	744	0	0	0	-	-	-	-
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Termination of Teva agreement through cancellation of common shares (note 13c)
-	-	-	-	-	4,470	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-